These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27914235)

  • 1. Hyaluronan as a promising excipient for ocular drug delivery.
    Guter M; Breunig M
    Eur J Pharm Biopharm; 2017 Apr; 113():34-49. PubMed ID: 27914235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid in ocular drug delivery.
    Zhang X; Wei D; Xu Y; Zhu Q
    Carbohydr Polym; 2021 Jul; 264():118006. PubMed ID: 33910737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An insight on hyaluronic acid in drug targeting and drug delivery.
    Yadav AK; Mishra P; Agrawal GP
    J Drug Target; 2008 Feb; 16(2):91-107. PubMed ID: 18274931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronan: an overview.
    Abbruzzese F; Basoli F; Costantini M; Giannitelli SM; Gori M; Mozetic P; Rainer A; Trombetta M
    J Biol Regul Homeost Agents; 2017 Dec; 31(4 Suppl 2):9-22. PubMed ID: 29202559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of hyaluronan and its ophthalmic applications.
    Rah MJ
    Optometry; 2011 Jan; 82(1):38-43. PubMed ID: 21146792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid for anticancer drug and nucleic acid delivery.
    Dosio F; Arpicco S; Stella B; Fattal E
    Adv Drug Deliv Rev; 2016 Feb; 97():204-36. PubMed ID: 26592477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic conjugated polymer/fluoresceinamine-hyaluronan complex for sensitive fluorescence detection of CD44 and tumor-targeted cell imaging.
    Huang Y; Yao X; Zhang R; Ouyang L; Jiang R; Liu X; Song C; Zhang G; Fan Q; Wang L; Huang W
    ACS Appl Mater Interfaces; 2014; 6(21):19144-53. PubMed ID: 25278260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel bioadhesive hyaluronan-itaconic acid crosslinked films for ocular therapy.
    Calles JA; Tártara LI; Lopez-García A; Diebold Y; Palma SD; Vallés EM
    Int J Pharm; 2013 Oct; 455(1-2):48-56. PubMed ID: 23911915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction between TS-polysaccharide and hyaluronic acid: implications in the formulation of eye drops.
    Uccello-Barretta G; Nazzi S; Zambito Y; Di Colo G; Balzano F; Sansò M
    Int J Pharm; 2010 Aug; 395(1-2):122-31. PubMed ID: 20580791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronan: pharmaceutical characterization and drug delivery.
    Liao YH; Jones SA; Forbes B; Martin GP; Brown MB
    Drug Deliv; 2005; 12(6):327-42. PubMed ID: 16253949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid-conjugated apoferritin nanocages for lung cancer targeted drug delivery.
    Luo Y; Wang X; Du D; Lin Y
    Biomater Sci; 2015 Oct; 3(10):1386-94. PubMed ID: 26301700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.
    Oh EJ; Park K; Kim KS; Kim J; Yang JA; Kong JH; Lee MY; Hoffman AS; Hahn SK
    J Control Release; 2010 Jan; 141(1):2-12. PubMed ID: 19758573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate-functionalized hyaluronic acid showing selective affinity for osteoclasts as a potential treatment for osteoporosis.
    Kootala S; Ossipov D; van den Beucken JJ; Leeuwenburgh S; Hilborn J
    Biomater Sci; 2015 Aug; 3(8):1197-207. PubMed ID: 26222035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses.
    Tashakori-Sabzevar F; Mohajeri SA
    Drug Dev Ind Pharm; 2015 May; 41(5):703-13. PubMed ID: 25113431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and syntheses of hyaluronan oligosaccharide conjugates as inhibitors of CD44-Hyaluronan binding.
    Lu X; Huang X
    Glycoconj J; 2015 Oct; 32(7):549-56. PubMed ID: 25997408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection.
    Gan L; Wang J; Zhao Y; Chen D; Zhu C; Liu J; Gan Y
    Biomaterials; 2013 Aug; 34(24):5978-87. PubMed ID: 23680367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in Topical Ocular Drug Delivery Systems: Hydrogels and Contact Lenses.
    Ribeiro AM; Figueiras A; Veiga F
    J Pharm Pharm Sci; 2015; 18(5):683-95. PubMed ID: 26670365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer.
    Skandalis SS; Gialeli C; Theocharis AD; Karamanos NK
    Adv Cancer Res; 2014; 123():277-317. PubMed ID: 25081534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation contact lenses: Towards bioresponsive drug delivery and smart technologies in ocular therapeutics.
    Chaudhari P; Ghate VM; Lewis SA
    Eur J Pharm Biopharm; 2021 Apr; 161():80-99. PubMed ID: 33607239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin.
    Brown MB; Jones SA
    J Eur Acad Dermatol Venereol; 2005 May; 19(3):308-18. PubMed ID: 15857456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.